Bedel Financial Consulting’s Amedisys AMED Stock Holding History

Bedel Financial Consulting’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3	Closed	-$1K	–	789
2020 Q1	$1K	Buy	+3	New	+$534	﹤0.01%	713

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bedel Financial Consulting's AMED Position: Q2 2020 in Review

Bedel Financial Consulting sold out of Amedisys (AMED) in Q2 2020, closing a stake of 3 shares — an estimated $1K sold.

Bedel Financial Consulting first reported a position in AMED in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 354 funds tracked by Wall St. Rank hold AMED as of Q2 2020.

Bedel Financial Consulting reported no remaining Amedisys position as of Q2 2020 after selling out during the quarter.
Bedel Financial Consulting sold 3 Amedisys shares in Q2 2020, an estimated $1K.
Bedel Financial Consulting first reported a position in Amedisys in Q1 2020 and held it in 1 quarter.
Bedel Financial Consulting's Amedisys position peaked at $1K in Q1 2020.
354 funds tracked by Wall St. Rank held Amedisys as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.